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Abstract
Background: Hypoxia inducible factor 1α (HIF-1α) plays an essential role in the adaptive response of cells to hypoxia 
and is associated with aggressive tumour behaviour. We have shown p27kip1, which is generally reduced in endometrial 
cancer, to be re-expressed in hypoxic regions. This possibly contributes to survival of cancer cells. The aim of this study 
was to evaluate the prognostic value of HIF-1α and p27kip expression in patients with endometrioid endometrial 
cancer.
Methods: Expression levels of HIF-1α, CAIX, Glut-1, and p27kip1 were analyzed by immunohistochemistry. Percentage 
of positive cells, staining pattern (perinecrotic, diffuse, or mixed) and presence of necrosis were noted.
Results: Necrosis was correlated with shortened disease free survival (DFS) (p = 0.008) and overall survival (OS) (p = 
0.045). For DFS, perinecrotic HIF-1α expression was also prognostic (p = 0.044). Moreover, high p27kip1 expression was 
an additional prognostic factor for these patients with perinecrotic HIF-1α expression. In multivariate Cox regression, 
perinecrotic HIF-expression emerged as an independent prognostic factor. Perinecrotic HIF-1α expression was 
significantly associated with CAIX and Glut-1 expression, pointing towards functional HIF-1.
Conclusions: In patients with endometrioid endometrial cancer, necrosis and necrosis-related expression of HIF-1α are 
important prognostic factors. More aggressive adjuvant treatment might be necessary to improve the outcome of 
patients with these characteristics.
Background
Endometrial cancer is the most common malignant
tumour of the female genital tract. The American Cancer
Society estimated that 42160 women have been diag-
nosed with, and 7780 women have died of cancer of the
female genital tract in 2009 in the US[1]. In the endome-
trium different subtypes of cancer can develop. Endo-
metrioid endometrial carcinoma (EEC), or Type 1
cancers, are oestrogen dependent, often develop in a
background of atypical complex hyperplasia and account
for over 75% of cases. EEC patients generally have a good
prognosis, with low mortality for stage 1 disease (5-year
survival around 87%)[2]. However, survival drops in
higher stage of disease. Additional prognostic factors
could help to decide the need for adjuvant treatment and
to identify new treatment strategies.
Solid tumours outgrow their own vasculature beyond
the size of several mm3, resulting in hypoxia. Regions of
necrosis are believed to demarcate regions of severe,
chronic hypoxia[3]. Hypoxia is an important issue in car-
cinogenesis because it renders a more aggressive pheno-
type with increased invasiveness and proliferation,
formation of metastases and poorer survival[4-8].
Besides, hypoxic malignant cells are more resistant to
radiotherapy and chemotherapy[9-11]. In reaction to
hypoxia, cells will alter their metabolism and activate cer-
tain survival genes. Hypoxia inducible factor 1 (HIF-1)
plays an essential role in the adaptive cellular response to
hypoxia[12,13]. HIF-1 is a transcription factor composed
of the subunits HIF-1α and HIF-1β, which are basic helix-
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loop-helix DNA binding proteins. HIF-1β is constitu-
tively expressed at the protein level. The activity of HIF-1
is predominantly regulated at the post-translational level
by regulating HIF-1α protein stability. Under normoxia,
HIF-1α is hydroxylated by prolyl hydroxylases in the oxy-
gen dependent degradation domain. Hydroxylated HIF-
1α is recognized by the Von Hippel Lindau protein, ubiq-
uitinated, and destined for degradation by the protea-
some. This process is inhibited during hypoxia[14], where
stabilized HIF-1α heterodimerizes with HIF-1β to trans-
activate target genes after nuclear translocation by bind-
ing to the consensus Hypoxia Responsive Element (HRE)
5'-RCGTG-3' in promoters and enhancers[15]. Among
these are growth factors, glucose transporters, glycolytic
enzymes, and genes involved in gluconeogenesis, high-
energy phosphate metabolism, erythropoiesis, haem
metabolism, iron transport, vasomotor regulation and
nitric oxide synthesis[13,15-17]. Protein products of
these downstream genes help the cell to survive the
hypoxic stress by increasing oxygen delivery (angiogene-
sis) and by switching to anaerobic glycolysis.
P r e v i o u s  b r e a s t  c a n c e r  s t u d i e s [ 6 , 7 ]  s h o w e d  t h a t  i n
hypoxic conditions, HIF-1α expression is seen perine-
crotically, with induction of its target genes carbonic
anhydrase 9 (CAIX), that plays a role in pH regulation[18]
and Glut-1, a transmembrane glucose transporter [19,20].
In normoxic conditions, HIF-1α expression can also be
induced by other mechanisms, but was to a much lesser
extent associated with downstream activation. CAIX and
Glut-1 thereby serve to identify functional HIF-1α[7]. In
b r e a s t  c a n c e r ,  w e  s h o w e d  t h a t  p a t i e n t s  w i t h  a  d i f f u s e
(non-hypoxia associated) HIF-1α staining pattern had a
relatively better prognosis[7]. Elevated levels of CAIX are
predictive of hypoxia in various types of cancer and are
related to poor prognosis[21,22]. The prognostic value of
CAIX and Glut-1 has not been studied in endometrial
cancer. We previously suggested that HIF-1α plays an
important role in endometrial carcinogenesis[23]. In
postmenopausal woman, HIF-1α was increasingly over-
expressed from inactive endometrium through hyperpla-
sia to endometrioid carcinoma, paralleled by activation of
its downstream genes. HIF-1α overexpression has further
been shown to be correlated with a poorer survival in
cancers of the brain[24], cervix[25] and ovary[26]. As
H I F - 1 α  i s  r e l a t e d  t o  p o o r  c l i n i c a l  o u t c o m e  i n  s o m e
tumours, HIF-1α expression could be used to identify
patients who are at risk of developing recurrent disease
and who may benefit from adjuvant therapy. Moreover,
targeting HIF-1α could be an attractive therapeutic strat-
egy with the potential for disrupting multiple pathways
crucial for tumour growth. In endometrial cancer, there
are some conflicting data concerning the prognostic rele-
vance of HIF-1α, probably due to varying methodology
and patient groups[27-30]. Whether the different HIF-1α
expression patterns have different prognostic implica-
tions in endometrial cancer is yet unknown.
In accordance with the need to decrease energy usage
under low oxygen conditions, hypoxia induces cell-cycle
arrest[31]. Cell-cycle arrest is regulated by complex inter-
actions between cyclins, cyclin-dependent kinases
(CDKs), and cyclin-dependent kinase inhibitors
(CKIs)[32]. p27kip1 is a CKI that regulates progression
from G1 to S phase by inhibiting a variety of cyclin-CDK
complexes. It has been shown that p27kip1 expression is
strongly reduced in endometrial cancer[33,34]. In a
recent study on cell cycle regulation during endometrial
carcinogenesis[23], p27kip1 protein was re-expressed in
necrotic (i.e. hypoxic) areas of endometrial carcinomas.
We showed that p27kip1 re-expression by hypoxia was
HIF-1α-dependent and led to cell cycle arrest. This possi-
bly contributes to survival of cancer cells in hypoxic parts
of the tumour[35].
Several studies demonstrated that loss of the p27kip1
protein, as assessed by immunohistochemistry, is a nega-
tive prognostic marker in malignancies[36,37]. However,
the prognostic importance of HIF-1α induced re-expres-
sion of p27kip1 is not known. Loss of p27kip1 expression in
endometrial carcinoma did not seem to correlate with
worse prognosis in previous studies[38,39].
Understanding the mechanisms of carcinogenesis and
progression of endometrial cancer is important as these
insights might lead to improved diagnostic tools for the
pathologist, improved prediction of prognosis and
response to therapy, and eventually better biology-based
disease management in the individual patient. The aim of
this study was therefore to (1) re-evaluate the prognostic
value of HIF-1α with emphasis on expression patterns
and investigate the additional effect of p27kip1 expression
on predicting survival in EEC and (2) to determine rela-
tionships with the other clinicopathologic markers in the
endometrioid type of endometrial cancer.
Methods
Patients and Tissues
The study group, diagnosed between 1992 and 2005 at
the University Medical Centre Utrecht, The Netherlands,
was composed as follows: a search in our tumour bank for
patients with endometrioid endometrial cancer yielded
108 patients with paraffin embedded tumour tissue avail-
able. Patients with only endometrial sampling material
available were not included in our study. Furthermore,
p a t i e n t s  w e r e  e x c l u d e d  i f  t h e y  h a d  a  s e c o n d  p r i m a r y
tumour of the cervix or ovary (n = 3), or a history of cer-
vical carcinoma (n = 7). None of the patients received
preoperative radio- or chemotherapy. Patient chart
review was performed retrospectively; adequate follow-
up data were lacking for 5 patients, leaving 93 patients.
Table 1 gives an overview of the patient demographicsSeeber et al. BMC Cancer 2010, 10:307
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Table 1: Patient demographics and main pathological 
features of the group of endometrioid endometrial cancer 
patients (n = 93).
Variable Grouping N (%)
Age Mean 62.51
Minimum 31
Maximum 88
Stage I 54 (58)
II 21 (23)
III 13 (14)
IV 5 (5)
Grade 1 28 (30)
24 7 ( 5 1 )
31 8 ( 1 9 )
Depth of myometrial invasion 0 3 (3)
<50% 50 (54)
>50% 40 (43)
Necrosis Present 70 (75)
Absent 23 (25)
HIF-1α expression <1% 0 (0)
≥1% 93 (100)
<35% 74 (80)
≥35% 19 (20)
HIF-1α expression pattern§ Purely Perinecrotic 20 (21)
Purely Diffuse 39 (42)
Mixed 34 (37)
CAIX Positive 71 (76)
Negative 22 (24)
Glut-1 Positive 76 (81)
Negative 17 (19)
p27kip1 Positive 86 (93)
Negative 7 (7)
Follow up time (for surviving 
patients, in months)
Minimum 13
Maximum 182
Mean 66
and main pathological features. Haematoxylin and eosin-
stained sections were revised and histologically graded.
The tumour stage was defined by the International Feder-
ation of Gynaecologists and Obstetricians (FIGO) sys-
tem. Anonymous use of redundant tissue for research
purposes is part of the standard treatment agreement
with patients in our hospital[40].
Immunohistochemistry
Immunohistochemistry was performed on serial 4-μm
tick paraffin slides. Table 2 presents all antibodies, dilu-
tions, incubation times, and antigen-retrieval methods
used. For all stainings, slides were deparaffinized with
xylene and serial ethanol dilutions, and endogenous per-
oxidase activity was blocked in a buffer solution of pH 5.8
with hydrogen peroxide followed by antigen retrieval. For
HIF-1α, antigen retrieval was performed with EDTA buf-
fer pH 9.0 for 20 minutes at boiling temperature. After a
cooling down period of 20 minutes, slides were incubated
with a protein block (Vision Biosystems, Novocastra Lab-
oratories Ltd, Newcastle Upon Tyne, United Kingdom)
for 5 minutes, followed by anti-HIF-1α antibody (mouse
monoclonal, BD Transduction Laboratories, dilution
1:50, overnight 4°C). Incubation with the secondary anti-
body (Post Primary block, Novocastra) for 30 minutes
was preceded by incubation of Novolink™ polymer
(Novocastra) for 30 minutes. For p27kip1 staining, antigen
retrieval was performed with citrate buffer, pH 6.0, for 20
minutes at boiling temperature. After a cooling down
period of 20 minutes the slides were incubated with the
primary antibody (Kip1/p27, BD Transduction Laborato-
ries; dilution 1:500, overnight 4°C) followed by the sec-
ondary antibody (Powervision, ImmunoVision
Technologies, Brisbane, CA, USA; ready to use, 30 min-
utes) as before[35]. For CAIX and Glut-1 staining proto-
cols were used as before[6,7,23]. Slides were developed
Recurrence/Metastasis Yes 18 (19)
No 72 (78)
Missing 3 (3)
Survival Alive 71 (76)
Death of 
endometrial cancer
11 (12)
Death of 
intercurrent 
disease
10 (11)
Cause of death 
unknown
1( 1 )
§ Perinecrotic HIF present = mixed and purely perinecrotic HIF 
pattern grouped.
Table 1: Patient demographics and main pathological 
features of the group of endometrioid endometrial cancer 
patients (n = 93). (Continued)S
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Table 2: Overview of the antibodies used and tissue processing details.
Primary Anti Body Type Anti Body Source Dilution Antigen Retrieval Second step Positive control Incubation time/temp (primary antibody) Procedure
HIF-1α MoAb Transdu
ction
1:50 EDTA, Ph9.0, 20 
minutes, 93°C
NV mamma o/n 4°C By hand
Glut-1 PoAb, Rabbit DAKO 1:200 Citrate, Ph6.0, 20 
minutes, 93°C
G-AR IgG + 
strep 1
Placenta 60 minutes/room temp Autostainer
CAIX PoAb, Rabbit Abcam 1:1000 Citrate, Ph6.0, 20 
minutes, 93°C
PV Grawitz tumour 60 minutes/room temp By hand
p27kip1 MoAb Transdu
ction
1:500 Citrate, Ph6.0, 20 
minutes, 93°C
PV Skin o/n 4°C By hand
HIF-1α = hypoxia-inducible factor-1α; Glut-1 = glucose transporter-1; CAIX = carbonic anhydrase IX; MoAb = monoclonal antibody; PoAb = polyclonal antibody; Transduction = BD Transduction 
Laboratories, BD Biosciences, San Diego, CA, USA; DAKO = DAKOCytomation, Glostrup, Denmark; Abcam = Abcam, Cambridge Science Par, Cambridge, UK; G-aR IgG = biotinylated Goat-anti Rabbit 
IgG (BA-1000, Vector laboratories, CA, diluted 1:500) + strep 1 = Streptavidin peroxidase labelling (Streptavidin HRP IM0309, Beckman Coulter, diluted 1:100); NV = Novolink™ polymer (Novocastra); 
PV = Powervision ready to use (Poly-HRP-anti Ms/Rb/RtlgG biotin free, ImmunoLogic, ImmunoVision technologies, Brisbane CA, USA).Seeber et al. BMC Cancer 2010, 10:307
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with diaminobenzidine for 10 minutes, followed by hae-
matoxylin counterstaining. In between steps, slides were
washed in PBS. Before the slides were mounted, all sec-
tions were dehydrated in alcohol and xylene. Appropriate
positive and negative controls were used throughout.
Evaluation of Staining
Scoring was performed by two observers (PJvD, LS) as
before[6,7,23]. Stainings were scored blinded to clinico-
pathologic data and results of other stainings. For HIF-1α
and p27kip1, the percentage of dark, homogenously
stained nuclei was estimated, ignoring cytoplasmic stain-
ing. Both were considered positive when ≥1% staining
was seen. Glut-1 and CAIX were considered positive
when membrane staining was seen. The pattern of HIF-
1α, Glut-1 and CAIX was noted as purely diffuse
(throughout the tumour without emphasis on areas with
necrosis, thought to be due to non-hypoxic stimuli),
perinecrotic (only positive staining around a necrotic
area, thought to be hypoxia induced) or a combination of
these two ("mixed"). No double staining was performed
as this was done previously in breast cancer, and no fur-
ther topographic analysis of staining was performed[7].
For p27kip1, the pattern of staining was noted as perine-
crotic, centrally in tumour islands (as these may be pre-
necrotic areas), diffuse or mixed.
Statistical Analysis
The Chi-square test or Fisher's Exact test (when appro-
priate) were used to evaluate correlations between HIF-
1α expression, presence of necrosis, p27kip1 expression
and stage, grade, myometrial invasion. Correlations
between HIF-1α, CAIX and Glut-1 expression were eval-
uated with McNemar's test and Spearman rank correla-
tion coefficient. Mann-Whitney-U was used to assess
HIF-1α expression and age at time of diagnosis. For uni-
variate survival analysis, the HIF-1α staining pattern or
the 75% percentile (35%) was chosen as cut-off value for
HIF-1α and p27kip1 expression, closely corresponding to
the proportion of patients that remained alive and well
(81%). Kaplan-Meier curves were plotted, and differences
between the curves were analyzed with the log-rank test
to test disease-free survival (DFS) and overall survival
(OS). Cox proportional hazard was used for the multivar-
iate survival analysis entering stage, grade, myometrial
invasion, age, perinecrotic HIF-1α and p27kip1 expression
as covariates. Two sided uncorrected p-values < 0.05 were
considered statistically significant. All analysis were per-
formed with SPSS for Windows version 15.0; SPSS Inc.,
Chicago, IL, USA.
Results
HIF-1α and necrosis
Detectable levels of HIF-1α were found in all endometrial
carcinomas. The mean level of nuclear staining for HIF-
1α was 26% (median, 20%; range, 1-90%). 20/93 cases
(21%) showed a purely perinecrotic staining pattern, 39/
93 (42%) a purely diffuse pattern, and 34/93 (37%)
showed a mixed (diffuse and perinecrotic) pattern (figure
1). Necrosis was found in 73/93 (75%) of the endometrial
carcinomas. Not all tumours with necrosis showed
perinecrotic HIF-1α expression.
Presence of perinecrotic HIF-1α expression was signifi-
cantly associated with high-grade tumours (table 3). Nine
out of 28 tumours (32%) showed perinecrotic HIF-1α
expression in grade 1 tumours compared with 70% grade
2 and grade 3 tumours (χ2-test, p = 0.004). HIF-1a expres-
sion in endometrioid endometrial cancer was not stage
dependent and there was no association of perinecrotic
HIF-1α expression and depth of myometrial invasion or
age. Similarly, necrosis was more often seen in high grade
than in low grade tumours (χ2-test, p = 0.003). No associ-
ation was found between necrosis and tumour stage,
depth of myometrial invasion or age.
p27kip1 protein expression
Expression of p27kip1 was found in 86/93 (93%) of endo-
metrial carcinomas (figure 1). The mean level of nuclear
staining for p27kip1 was 24% (median, 20%; range 0-100%).
There was no correlation between percentage p27kip1 pos-
itive cells and stage, grade, age, HIF-1α expression pat-
tern or necrosis (additional file 1). In 56% of the tumours
(30/54) with perinecrotic HIF-1α expression, we
observed central/perinecrotic p27kip1  staining (McNe-
mar; p < 0.0001). p27kip1 staining pattern did not correlate
with age, stage or myometrial invasion. However, perine-
crotic/central p27kip1 expression pattern was correlated
with higher grade (p = 0.046).
CAIX and Glut-1 expression in relation with HIF-1α
CAIX was expressed in 71/93 (76%) cases. Glut-1 showed
membranous expression in 76/93 (81%) cases. Positive
expression of both CAIX and Glut-1 was seen in 68% of
the perinecrotic HIF-1α expressing tumours compared to
32% of the diffuse group (χ2-test, 0.007). Perinecrotic
HIF-1α expression was also significantly associated with
CAIX or Glut-1 expression (McNemar; p = 0.004 respec-
tively p < 0.0001).The 54 cases with any perinecrotic HIF-
1α expression showed positive expression of CAIX or
Glut-1 in 47/54 and 48/53 cases, respectively. Diffuse
HIF-1α expression was accompanied by CAIX expression
in 24/39 or Glut-1 expression in 28/39 cases. Levels of
HIF-1α expression correlated with expression levels of
CAIX ( Spearman; p = 0.012) but not with expression lev-
els of Glut-1.
Survival analysis results
Locoregional recurrences (vaginal, pelvic, or both) or dis-
tant metastases were found in 18 of 93 patients. Three
patients with unknown recurrence status were censoredSeeber et al. BMC Cancer 2010, 10:307
http://www.biomedcentral.com/1471-2407/10/307
Page 6 of 11
Figure 1 Immunohistochemical staining of HIF-1α, CAIX, Glut-1 and p27kip1 in endometrioid endometrial carcinoma. Typical patterns are 
shown: A) perinecrotic HIF-1α expression (10× magnification). B) Diffuse HIF-1α expression (10× magnification). C) Diffuse p27kip1 expression (10× 
magnification). D) Perinecrotic Glut-1 expression (10× magnification) E) Membrane CAIX expression (20× magnification). Asterisk indicates necrosis.Seeber et al. BMC Cancer 2010, 10:307
http://www.biomedcentral.com/1471-2407/10/307
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Table 3: Associations between HIF-1α staining pattern, clinicopathological features and expression of CAIX, Glut-1 and 
p27kip1.
Perinecrotic HIF-1α
Yes (%) No (%) P-value
Stage I 30 (56) 24 (44)
II 12 (57) 9 (43) 0.845
III 9 (69) 4 (31)
IV 3 (60) 2 (40)
Grade 1 9 (32) 19 (68)
2 33 (70) 14 (30) 0.004
3 12 (67) 6 (33)
Myometrial Invasion 0 0 3 (100)
<50% 29 (58) 21 (42) 0.107
>50% 25 (63) 15 (37)
Necrosis Yes 54 (77) 16 (23) <0.0001
No 0 23 (100)
Recurrence/Metastasis Yes 14 (79) 4 (22) 0.043
No 37 (51) 35 (49)
p27kip1 Pos 48 (89) 38 (97) 0.125
Neg 6 (11) 1 (3)
p27kip1 ≤50% 48 (58) 35 (42) 0.896
>50% 6 (60) 4 (40)
p27kip1 expression pattern Peri/central 30(91) 3(9) <0.0
Other* 24(40) 36(60) 001
CAIX Pos 47 (67) 24 (33) 0.004
Neg 7 (32) 15 (68)
Glut-1 Pos 48 (63) 28 (37) 0.035
Neg 6 (35) 11 (65)
CAIX and Glut-1 Pos 42 (68) 20 (32) 0.007
Neg 12 (39) 19 (61)
HIF-1α = hypoxia-inducible factor 1α; CAIX = carbonic anhydrase IX; Glut-1 = glucose transporter 1, * other staining patterns include diffuse 
staining or negative for p27kip1.Seeber et al. BMC Cancer 2010, 10:307
http://www.biomedcentral.com/1471-2407/10/307
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Figure 2 Kaplan-Meier survival curves illustrating disease-free survival and overall survival for endometrioid endometrial carcinoma pa-
tients (n = 93) with tumour necrosis (A, B) and patients with perinecrotic type HIF-1α expression (C, D). E and F show the survival for the pa-
tients with perinecrotic HIF-1α expression (n = 51) and high p27kip1 expression. Stage and grade show prognostic value as expected in G - J.Seeber et al. BMC Cancer 2010, 10:307
http://www.biomedcentral.com/1471-2407/10/307
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for disease free survival analysis. Stage and grade showed
prognostic value as expected, underlining the representa-
tiveness of the patient group (see Figure 2). Univariate
analysis (Kaplan-Meier, log rank test) for the whole group
of patients showed that necrosis was correlated with
shortened disease free survival (DFS) (p =  0.008) and
overall survival (OS) (p = 0.045). For DFS, perinecrotic
HIF-1α expression also was prognostic (p =  0.044), as
shown in figure 2. HIF expression in more than 35% of
cells was associated with a shorter OS (p = 0.032). CAIX
expression was not correlated with survival. Membra-
nous Glut-1 expression however correlated with a shorter
DFS (p = 0.037). Subgroup analysis of low stage (stage I
and II) (n = 75) patients did show perinecrotic HIF-1α
expression also to be an indicator of shorter disease free
survival in this patient group (p = 0.033), while signifi-
cance was lost in the stage III/IV (n = 18) subgroups (p =
0.737).
P27kip1 expression or expression pattern had no signifi-
cant relation to prognosis. Subgroup analysis of patients
with perinecrotic HIF-1α expression (n  = 55) revealed
that high p27kip1 expression (>50% positive cells) was an
additional prognostic factor indicating a poor prognosis
for DFS (p = 0.007) and OS (p = 0.002) in this subgroup.
In a multivariate model together with stage, grade,
depth of myometrial invasion and age at diagnosis, only
perinecrotic HIF-1α expression emerged as an additional
prognostic factor to stage and age for DFS (p = 0.044; RR:
0.312; 95% Confidence Interval 0.100-0.972). Multivariate
analysis of patients with perinecrotic HIF-1α expression,
showed high p27kip1 t o  be  a  p r ogn os t i c  fa ct o r  f o r  D F S
above stage and age (p = 0.011; RR: 6.735 95% Confidence
Interval 1.557-29.122).
Discussion
Hypoxia and its key regulator HIF-1α have been shown to
play an important role in endometrial carcinogenesis[23],
but contradictory results have been published as to the
prognostic value of HIF-1α overexpression in endome-
trial carcinoma[27-30], while expression patterns have
been ignored. The aim of this study was therefore to re-
evaluate the prognostic value of HIF-1α overexpression
in a representative group of patients with endometrioid
endometrial cancer, with emphasis on expression pat-
terns. Also, as p27kip1 is re-expressed in hypoxic regions
of EEC[35], we investigated the additional effect of p27kip1
expression on predicting survival in EEC. HIF-1α overex-
pression, especially the perinecrotic type, and necrosis
appeared to be independent indicators of poor prognosis.
High p27kip1 (>50% positive cells) expression was an addi-
tional prognostic factor in the subgroup of patients with
perinecrotic type of HIF-1α expression.
Our results on the prognostic value of HIF-1α overex-
pression are in line with those of Sivridis et al.[27] where
HIF-1α was associated with a shorter overall survival in
stage 1 endometrial cancer. However, others did not find
a significant prognostic impact of HIF-1α overexpres-
sion[28-30]. Immunohistochemical HIF-1α studies are
difficult to compare because of a variation in the defini-
tion of HIF-1α positivity. Previous studies did not con-
sider the different expression patterns throughout the
tumours (diffuse versus perinecrotic) that have been
shown in other cancers to be prognostically crucial[7].
Another difference between the present and previous
studies is the cut off value for HIF-1α expression. In the
present study, the cut off value for prognostic value of
HIF-1α was 35%, much higher than in other studies
where the cut off varied between 1% and 5%[6,41]. Our
results indicate that also in endometrial cancer, the pat-
tern of HIF-1α expression is more important for the
prognosis than percentage and intensity of HIF-1α
expressing cells in general. This significance of expression
pattern could be explained by the fact that perinecrotic
HIF-1α expression is thought to be hypoxia driven,
whereas diffuse HIF-1α expression may rather be due to
non-hypoxic stimuli[6,7]. In a previous study from our
group[23] we showed that diffuse HIF-1α expression was
associated with the highest microvessel density (MVD);
perinecrotic and mixed patterns were associated with an
intermediate MVD (p < 0.05). This indicates that diffuse
HIF-1α expression is more likely to be due to non-
hypoxic stimuli than to non-necrosis associated hypoxia.
We showed that perinecrotic HIF-1α expression is more
often accompanied by activation of its downstream fac-
tors Glut-1 and CAIX, indicating it to be more active than
diffuse HIF-1α. More activation of HIF-1α and its target
genes would give more tumour cells a survival advantage
in a hypoxic environment. Perinecrotic HIF-1α expres-
sion retained its prognostic significance in the subgroup
of low stage, while significance was lost in stage III/IV
patients, indicating that HIF-1α expression seems to be
especially important in low stage patients. However, sam-
ple size of the subgroups (especially the high stages) was
limiting. Therefore, no definitive conclusions on the
prognostic value of HIF-1α in high stage patients can be
made. Loss of p27kip1 expression has been reported for a
number of human tumour types and has been correlated
with poor prognosis and tumour aggressiveness[36,42].
Only one study showed a correlation between p27kip1
expression and prognosis in endometrial cancer[43].
However, we found no prognostic influence of global
p27kip1  expression in endometrioid endometrial carci-
noma. This is in line with the outcome of oth-
ers[38,39,44]. Since we found hypoxia to be able to induce
re-expression of p27kip1 in a HIF-1α dependent way in a
previous study[35], we evaluated the prognostic value of
p27kip1 in relation to HIF-1α in the present study. In the
s u b g r o u p  o f  p a t i e n t s  w i t h  pe r i n ec r o t i c  H I F - 1 α  e x p r e s -Seeber et al. BMC Cancer 2010, 10:307
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sion, high p27kip1 expression (>50% positive cells) was
associated with a shorter DFS and OS. This fits with our
previously proposed model that hypoxia induced re-
expression of p27kip1 may result in dormancy of hypoxic
cells, which in combination with HIF-1α induced expres-
sion of genes regulating supply of energy, growth factors
and other survival factors, may promote cellular survival
and adaptation of sub clones within the tumour that may
c o n t ri b u t e  t o  m e tas t a t i c  d is eas e  a n d  poo r  c l i n i ca l  o u t -
come. In our previous study however, only central/
perinecrotic p27kip1 expression was associated with HIF-
1α induced re-expression[35]. In the present study, cen-
tral/perinecrotic p27kip1 expression was still associated
with perinecrotic HIF-1α expression; however this sub-
group was too small to correlate with survival data.
Interestingly, all patients lacking tumour necrosis sur-
vived, and none of these patients developed a locore-
gional or distant recurrence. The prognostic value of
necrosis is in concordance with previous results by Schol-
ten et al.[45] who showed that necrosis is a significant
prognostic factor in Stage I-III endometrioid endometrial
carcinoma. Although necrosis is a strong independent
prognostic factor for endometrial carcinoma, its clinical
use may be limited because of a moderate reproducibil-
ity[45-47]. Further, excluding the presence of necrosis
requires adequate sampling. More objective biomarkers
like perinecrotic HIF-1α expression could result in a
higher reproducibility.
Conclusions
We conclude that in endometrioid endometrial carci-
noma, absence of necrosis is a favourable prognostic fac-
tor. Tumours with a perinecrotic HIF-1 expression are
more aggressive than tumours with purely diffuse HIF-1
expression. Furthermore, the combination of perinecrotic
HIF expression and high p27kip1 expression is indicative
for an unfavourable prognosis. More aggressive adjuvant
treatment might be necessary to improve the outcome of
these patients. To this end, targeting the HIF pathway
might provide an attractive strategy to treat hypoxic and
highly angiogenic tumours. Thus far, selective HIF-1
inhibitors have not been identified. A number of non-
selective inhibitors, which indirectly target signaling
pathways upstream or downstream of HIF-1 are known
to decrease the key regulating HIF-1α protein levels. Pre-
liminary results show encouraging results for these single
agent treatments, however severe toxicities have been
encountered. Lack of specificity increases the difficulty in
attributing any anti-tumorigenic effects of these drugs
specifically to inhibition of HIF-1. Further studies are
needed to show whether adaptation of therapy protocols
might be of benefit for endometrial cancer patients with
perinecrotic HIF-1α overexpression.
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